Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 1/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | HKDC1 | Q2TB90 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.40 |
| ▸ | MAPT | P10636 | 5/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | TP53 | P04637 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | CDC25A | P30304 | 1/20 | 0.38 |
| ▸ | CDC25B | P30305 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL49737 | 0.81 | ERBB2 (0.62) | ERBB2PTPN1HKDC1KDM4ECYP3A4 | |
| SCHEMBL28259188 | 0.78 | ERBB2 (0.59) | ERBB2PTPN1HKDC1KDM4ECYP3A4 | |
| SCHEMBL28856262 | 0.78 | ERBB2 (0.59) | ERBB2PTPN1HKDC1KDM4ECYP3A4 | |
| SCHEMBL8958289 | 0.70 | MALT1 (0.50) | PTPN1ALOX15ALDH1A1HSD17B10MALT1 | |
| SCHEMBL3417111 | 0.70 | HKDC1 (0.56) | ERBB2PTPN1HKDC1KDM4ECYP3A4 | |
| Coprinin SCHEMBL3416504 | 0.70 | ERBB2 (0.50) | ERBB2PTPN1HKDC1KDM4ECYP3A4 | |
| SCHEMBL30092600 | 0.70 | ERBB2 (0.45) | ERBB2PTPN1HKDC1KDM4ECYP3A4 | |
| SCHEMBL23751954 | 0.68 | ERBB2 (0.48) | ERBB2PTPN1HKDC1KDM4ECYP3A4 | |
| SCHEMBL17261224 | 0.68 | ERBB2 (0.48) | ERBB2PTPN1HKDC1KDM4ECYP3A4 | |
| SCHEMBL11025815 | 0.67 | MAPT (0.50) | ERBB2PTPN1HKDC1KDM4ECYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250263384-A9 | REDOX-ACTIVE COMPOUNDS AND USES THEREOF | CMBLU ENERGY AG (DE) | 2025-08-21 | — | — | US | disclosed |
| US-20240124405-A1 | REDOX-ACTIVE COMPOUNDS AND USES THEREOF | CMBLU PROJECKT AG (DE) | 2024-04-18 | — | — | US | disclosed |
| US-11731945-B2 | Redox-active compounds and uses thereof | CMBLU ENERGY AG (DE) | 2023-08-22 | — | — | US | disclosed |
| US-11731945-B2 | Redox-active compounds and uses thereof | CMBLU ENERGY AG (DE) | 2023-08-22 | — | — | US | disclosed |
| US-20230095542-A1 | Novel Phenazine-Based Compounds | CMBLU ENERGY AG (DE) | 2023-03-30 | — | — | US | disclosed |
| EP-4107147-A1 | NOVEL PHENAZINE-BASED COMPOUNDS | CMBlu Energy AG (DE) | 2022-12-28 | — | — | EP | disclosed |
| US-20210253540-A1 | REDOX-ACTIVE COMPOUNDS AND USES THEREOF | CMBLU PROJEKT AG (DE) | 2021-08-19 | — | — | US | disclosed |
| US-20210253540-A1 | REDOX-ACTIVE COMPOUNDS AND USES THEREOF | CMBLU PROJEKT AG (DE) | 2021-08-19 | — | — | US | disclosed |
| CN-113166079-A | Redox active compounds and their use | 克姆布鲁项目公司 | 2021-07-23 | — | — | CN | disclosed |
| EP-3837246-A2 | REDOX-ACTIVE COMPOUNDS AND USES THEREOF | CMBlu Projekt AG (DE) | 2021-06-23 | — | — | EP | disclosed |
| WO-2020035548-A2 | REDOX-ACTIVE COMPOUNDS AND USES THEREOF | CMBLU PROJEKT AG (DE) | 2020-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124405-A1 | REDOX-ACTIVE COMPOUNDS AND USES THEREOF | NOX4, NQO1, GPX1 | ERBB2 4083/4885PTPN1 2740/4885HKDC1 1895/4885 |
| US-20230095542-A1 | Novel Phenazine-Based Compounds | PRDX5, NDUFS5, GPX4 | ERBB2 1517/4885PTPN1 1847/4885HKDC1 839/4885 |
| US-20250263384-A9 | REDOX-ACTIVE COMPOUNDS AND USES THEREOF | NOX4, NQO1, GPX1 | ERBB2 4083/4885PTPN1 2740/4885HKDC1 1895/4885 |
| US-11731945-B2 | Redox-active compounds and uses thereof | NOX4, NQO1, GPX1 | ERBB2 4083/4885PTPN1 2740/4885HKDC1 1895/4885 |
| US-20210253540-A1 | REDOX-ACTIVE COMPOUNDS AND USES THEREOF | NOX4, NQO1, GPX1 | ERBB2 4083/4885PTPN1 2740/4885HKDC1 1895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.